Regeneron fell 11.6% in premarket trading on Monday after its experimental melanoma treatment failed to meet the main goal in a late-stage head-to-head trial. The failure follows regulatory delays for Eylea and a late-stage miss for Regeneron's lung disease treatment itepekimab last year. Back-to-back pipeline setbacks increase pressure on Regeneron's clinical development timeline over the next 12 to 18 months.

Clinical Data Fails to Reach Statistical Significance